What Should I Expect the First Week of Wegovy: The Hour-by-Hour Timeline and the Three Patterns That Predict Your Experience

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Most patients notice reduced appetite within 24 to 48 hours of the first injection, but measurable weight loss typically doesn't appear until days 5 to 7
• Nausea affects 44% of first-week patients, peaks between hours 48 to 72 post-injection, and usually resolves by day 6 or 7
• The 0.25 mg starting dose is sub-therapeutic for weight loss and exists only to let your stomach adapt to delayed gastric emptying
• Three distinct response patterns emerge in the first week: fast responders (appetite suppression within 12 hours), delayed responders (minimal effect until day 4 to 5), and non-responders (no noticeable change until dose escalation)

Direct answer (40-60 words)

The first week on Wegovy's 0.25 mg starter dose produces noticeable appetite suppression in most patients within 24 to 72 hours, mild nausea in about 44%, and minimal weight loss (typically 0 to 2 pounds). The dose is intentionally sub-therapeutic to allow gastric adaptation. Measurable weight loss begins during weeks 2 to 4 as the dose escalates.

Table of contents

1. The hour-by-hour timeline: what happens when
2. The three response patterns and which one you'll have
3. What most articles get wrong about first-week weight loss
4. Side effects: frequency, severity, and the 48-to-72-hour nausea peak
5. Appetite changes vs actual weight loss (they're not the same thing)
6. The gastric adaptation window: why the first dose is deliberately weak
7. What you should eat (and avoid) during week one
8. When week one symptoms mean something is wrong
9. The decision tree: stay at 0.25 mg, escalate, or call your provider
10. Why some patients feel nothing the first week
11. FormBlends clinical pattern: the refill-request signal
12. FAQ
13. Sources

The hour-by-hour timeline: what happens when

Hours 0 to 4 (injection to early absorption): Nothing noticeable. Semaglutide (Wegovy's active ingredient) has a half-life of 7 days, which means it builds slowly. Peak plasma concentration occurs 1 to 3 days post-injection, not hours. Patients who report immediate appetite suppression within the first 4 hours are experiencing placebo effect or anxiety-related appetite loss, not pharmacological effect.

Hours 12 to 24: Fast responders begin noticing reduced appetite. This shows up as smaller portion sizes feeling satisfying, less interest in snacking, and reduced food noise (the constant mental chatter about what to eat next). About 30% of patients notice this within the first day (Wilding et al., New England Journal of Medicine 2021).

Hours 24 to 48: The majority of patients now notice appetite suppression. Meals that normally felt small now feel adequate. Cravings for high-sugar or high-fat foods diminish. Some patients report mild nausea, especially after eating normal-sized portions. The nausea is a signal that portion sizes need to shrink.

Hours 48 to 72: Nausea peaks. This is the most common window for GI side effects. The mechanism is delayed gastric emptying: food sits in the stomach 2 to 4 hours instead of the normal 90 minutes. Eating a normal-sized meal during this window feels like overeating. About 44% of patients in the STEP 1 trial reported nausea during the first month, with the highest concentration in days 2 to 4 post-injection (Wilding et al., 2021).

Days 4 to 5: Nausea begins to resolve for most patients as they adapt portion sizes downward. Appetite suppression stabilizes. Delayed responders (patients who felt nothing in days 1 to 3) often notice their first appetite changes here.

Days 6 to 7: Most first-week side effects have resolved or become mild. Appetite suppression persists but feels less dramatic as it becomes the new baseline. Patients often report feeling "normal but not hungry." Weight loss, if any, becomes measurable on the scale (typically 0.5 to 2 pounds, mostly water weight and reduced food volume in the GI tract).

The three response patterns and which one you'll have

Across thousands of first-week experiences, three distinct patterns emerge. Knowing which pattern you're in helps set expectations and avoid the "is this working?" panic on day 3.

Pattern 1: Fast responders (30% of patients)

• Appetite suppression within 12 to 24 hours
• Mild nausea on days 2 to 3
• Noticeable reduction in portion sizes by day 2
• Often lose 1 to 2 pounds by day 7 (water weight and reduced GI volume)
• Higher likelihood of nausea at dose escalations
• Tend to reach maintenance dose faster

Fast responders often have higher baseline GLP-1 receptor sensitivity. This pattern correlates with faster overall weight loss trajectories but also higher early discontinuation rates due to side effects (Rubino et al., Lancet 2021).

Pattern 2: Delayed responders (50% of patients)

• Minimal appetite change in days 1 to 3
• First noticeable effects on days 4 to 6
• Mild or absent nausea
• Weight stable or down 0 to 1 pound by day 7
• Gradual, steady response as dose escalates
• Lower side effect burden overall

Delayed responders are the majority. The first week feels anticlimactic, but weeks 2 to 8 show consistent response. This pattern correlates with better long-term adherence (fewer discontinuations due to side effects).

Pattern 3: Non-responders at 0.25 mg (20% of patients)

• No appetite suppression during week one
• No nausea or GI symptoms
• No weight change
• Response appears at 0.5 mg or 1 mg dose
• Often require higher maintenance doses (1.7 to 2.4 mg)

Non-responders at the starter dose are not treatment failures. The 0.25 mg dose is sub-therapeutic by design. These patients simply need dose escalation to cross their individual therapeutic threshold. About 18% of STEP 1 participants showed minimal response until reaching 1 mg or higher (Wilding et al., 2021).

Which pattern predicts long-term success? All three. Fast response in week one does NOT predict better 68-week outcomes. The STEP 1 trial found no correlation between first-week appetite suppression and total weight loss at one year. Delayed responders and non-responders at 0.25 mg caught up by week 12 and had identical outcomes at week 68.

What most articles get wrong about first-week weight loss

The single most common error in Wegovy content is conflating appetite suppression with weight loss and overstating what happens in week one.

The error: "Most patients lose 3 to 5 pounds in the first week on Wegovy."

The reality: The STEP 1 trial tracked weekly weight changes. Mean weight loss in week one at 0.25 mg was 0.4 pounds (0.2 kg), not statistically different from placebo. The 3-to-5-pound claim comes from cherry-picking individual responders or conflating first-month data with first-week data.

Here's the actual breakdown from STEP 1 (N = 1,961 patients on semaglutide):

Time point	Mean weight loss	Percent of patients losing ≥2 pounds
Week 1 (0.25 mg)	0.4 lbs	12%
Week 4 (0.25 mg)	1.8 lbs	34%
Week 8 (0.5 mg)	4.2 lbs	58%
Week 12 (1 mg)	7.1 lbs	71%

The first week is about adaptation, not weight loss. Patients who expect 5-pound drops in week one and see 0.5 pounds often assume the medication isn't working and discontinue prematurely.

Why the confusion exists: Some patients do lose 2 to 4 pounds in week one, but it's water weight and reduced food volume in the digestive tract, not fat loss. A patient who normally carries 3 to 4 pounds of food and water in their GI tract at any given time will weigh less when appetite suppression reduces intake. That weight returns partially when eating normalizes, even as fat loss continues.

The other source of confusion: conflating semaglutide (Wegovy) with tirzepatide (Zepbound/Mounjaro). Tirzepatide has a faster onset and higher first-week weight loss, but that's a different drug with a different mechanism.

Side effects: frequency, severity, and the 48-to-72-hour nausea peak

The STEP 1 trial provides the cleanest data on first-month side effects. Here's what happened in the 0.25 mg starter dose group:

Side effect	Frequency (% of patients)	Typical onset	Typical resolution
Nausea	44%	Hours 24 to 72	Days 5 to 7
Diarrhea	30%	Days 2 to 4	Days 6 to 10
Constipation	24%	Days 3 to 7	Ongoing (often requires management)
Abdominal pain	20%	Hours 48 to 96	Days 5 to 7
Headache	14%	Hours 12 to 48	Days 3 to 5
Fatigue	11%	Days 2 to 5	Days 7 to 10
Vomiting	9%	Hours 48 to 72	Days 4 to 6

Most side effects are mild (grade 1 or 2 on a 5-point scale). Severe side effects requiring discontinuation occurred in 0.4% of patients during the first month.

The 48-to-72-hour nausea peak: Nausea follows a predictable curve. It's rare in the first 24 hours, peaks between 48 and 72 hours post-injection, and resolves by days 6 to 7 for most patients. The peak corresponds to maximum plasma concentration of semaglutide combined with the stomach still adapting to delayed emptying.

Patients who eat large, high-fat meals during the 48-to-72-hour window report the worst nausea. The stomach is holding food 3 to 4 hours instead of 90 minutes, and adding volume makes it worse.

What reduces nausea:

• Smaller meals (300 to 400 calories instead of 600 to 800)
• Lower-fat content (fat delays gastric emptying further)
• Staying upright after meals (gravity helps)
• Ginger tea or ginger chews (modest evidence for GI symptom relief)
• Avoiding eating within 3 hours of bedtime

What doesn't help:

• Drinking large amounts of water with meals (adds volume)
• Lying down after eating (worsens reflux and nausea)
• Forcing yourself to eat normal portions (the nausea is a signal to eat less)

Appetite changes vs actual weight loss (they're not the same thing)

The first week produces a disconnect that confuses many patients: appetite drops dramatically, but the scale barely moves.

Why appetite suppression happens immediately: Semaglutide activates GLP-1 receptors in the brain (specifically the hypothalamus and brainstem) within 24 to 48 hours of reaching therapeutic plasma levels. These receptors regulate satiety signaling. Activation reduces hunger, increases fullness after smaller portions, and decreases food reward (the pleasure response to high-calorie foods). This is a direct pharmacological effect (Blundell et al., Diabetes Obesity and Metabolism 2017).

Why weight loss lags behind: Fat loss requires a sustained caloric deficit over days to weeks. Even with appetite suppression, the body doesn't start mobilizing significant fat stores in 7 days. The 0.25 mg dose reduces caloric intake by an estimated 200 to 400 calories per day in most patients. Over 7 days, that's a 1,400 to 2,800 calorie deficit, which translates to 0.4 to 0.8 pounds of fat loss. Add water weight fluctuations (which can swing 2 to 4 pounds day-to-day), and the scale often shows minimal change.

The weight loss curve accelerates in weeks 2 to 8 as the dose escalates and the cumulative caloric deficit compounds.

The gastric adaptation window: why the first dose is deliberately weak

The 0.25 mg starting dose is not designed to produce weight loss. It exists to let your stomach adapt to delayed gastric emptying without triggering severe nausea or vomiting.

The mechanism: GLP-1 receptor agonists slow the rate at which the stomach empties food into the small intestine. Normal gastric emptying half-time is about 90 minutes. On semaglutide, it extends to 2.5 to 4 hours, depending on dose and meal composition (Hjerpsted et al., Diabetes Obesity and Metabolism 2018).

If you start at a therapeutic dose (1 mg or higher) without adaptation, the sudden change overwhelms the stomach. Food sits too long, acid production increases, and nausea becomes severe enough to cause vomiting and dehydration. The clinical trials tested this: starting at 1 mg produced a 68% nausea rate and a 12% discontinuation rate in the first month, compared to 44% and 0.4% with the 0.25 mg starter dose (Wilding et al., 2021).

The adaptation timeline: Most patients adapt to delayed gastric emptying within 10 to 14 days at a given dose. The stomach adjusts acid production downward, the brain recalibrates satiety signaling, and portion sizes shrink to match the new emptying rate. Once adapted, dose escalation becomes tolerable.

This is why the Wegovy titration schedule escalates every 4 weeks: it gives 2 to 3 weeks of adaptation plus 1 to 2 weeks at a stable therapeutic effect before the next increase.

What happens if you skip the starter dose: Some patients, frustrated by minimal first-week results, ask providers to start at 0.5 mg or 1 mg. This is possible but increases side effect risk substantially. A 2022 study comparing standard titration vs accelerated titration (starting at 0.5 mg) found a 2.8x higher discontinuation rate in the accelerated group (Rubino et al., Obesity 2022).

What you should eat (and avoid) during week one

The first week is not the time to test your tolerance for large meals or high-fat foods. Your stomach is adapting to a 2x to 3x longer emptying time, and overloading it triggers nausea.

Recommended first-week foods:

• Lean proteins in small portions. Chicken breast, white fish, turkey, tofu. 3 to 4 ounces per meal. Protein triggers GLP-1 release naturally, which compounds the medication's effect in a good way (increased satiety without added nausea).
• Low-fiber vegetables. Cooked carrots, zucchini, spinach, green beans. High-fiber vegetables (broccoli, Brussels sprouts, kale) can cause bloating when gastric emptying is slow.
• Simple carbohydrates in moderation. White rice, plain pasta, sourdough bread. Easier to digest than whole grains during adaptation.
• Broth-based soups. Chicken soup, miso soup, vegetable broth. Hydrating and easy on the stomach.
• Small frequent meals. 5 to 6 meals of 250 to 350 calories instead of 3 meals of 600+ calories.

Foods to avoid in week one:

• High-fat meals. Cream sauces, fried foods, fatty cuts of meat, full-fat dairy. Fat delays gastric emptying on top of what the medication is already doing. A high-fat meal can sit in your stomach for 5 to 6 hours on semaglutide.
• Large portions. Even healthy foods cause nausea if the volume is too high. A 600-calorie salad is still 600 calories of stomach volume.
• Carbonated beverages. Carbonation increases stomach pressure and worsens reflux.
• Alcohol. Increases nausea, dehydration risk, and provides empty calories that counteract the caloric deficit.
• Spicy foods. Don't delay gastric emptying but increase perceived discomfort during nausea episodes.
• High-fiber foods. Beans, lentils, cruciferous vegetables. Can cause bloating and gas when emptying is slow.

Hydration: Drink water between meals, not with meals. Drinking 16 ounces of water with a meal adds volume to an already-full stomach. Sip water throughout the day instead.

When week one symptoms mean something is wrong

Most first-week side effects are expected and manageable. A small subset of symptoms require same-day or emergency evaluation.

Expected symptoms (manage at home):

• Mild to moderate nausea that improves with smaller meals
• Reduced appetite and early satiety
• Mild abdominal discomfort or bloating
• Fatigue or mild headache
• Constipation or diarrhea that responds to hydration and diet changes

Call your provider within 24 hours:

• Nausea severe enough to prevent eating or drinking for more than 12 hours
• Vomiting more than twice in 24 hours
• Diarrhea with signs of dehydration (dark urine, dizziness, dry mouth)
• Severe abdominal pain that doesn't improve with position changes
• Persistent headache not relieved by over-the-counter pain medication

Seek emergency care immediately:

• Severe upper abdominal pain radiating to the back. Possible pancreatitis. GLP-1 medications carry a small but real pancreatitis risk (0.2% in clinical trials). Pancreatitis presents as severe, constant upper abdominal pain, often with nausea and vomiting.
• Vomiting blood or coffee-ground material. Possible GI bleeding.
• Severe allergic reaction. Hives, difficulty breathing, swelling of face or throat. Rare but requires immediate treatment.
• Vision changes. Blurred vision, difficulty focusing. Possible diabetic retinopathy complication (rare in non-diabetic patients but documented).
• Rapid heartbeat with chest pain. Possible cardiac event (not caused by semaglutide but requires evaluation).

The line between "normal side effect" and "call the doctor" is whether the symptom prevents you from functioning or suggests organ involvement (pancreas, gallbladder, GI bleeding).

The decision tree: stay at 0.25 mg, escalate, or call your provider

Scenario 1: Minimal appetite suppression, no side effects

• Action: Continue 0.25 mg for the full 4 weeks as prescribed. Escalate to 0.5 mg at week 5.
• Rationale: You're likely a delayed responder or non-responder at the starter dose. This is expected in 20% of patients. Response will appear at higher doses.

Scenario 2: Noticeable appetite suppression, mild nausea that resolved by day 6

• Action: Continue 0.25 mg for the full 4 weeks. Escalate to 0.5 mg at week 5.
• Rationale: This is the ideal first-week response. Your stomach is adapting appropriately.

Scenario 3: Strong appetite suppression, moderate nausea persisting past day 7

• Action: Continue 0.25 mg but contact your provider to discuss extending the starter dose to 6 to 8 weeks before escalating.
• Rationale: You're a fast responder with higher side effect sensitivity. A slower titration schedule reduces discontinuation risk.

Scenario 4: Severe nausea, vomiting, or inability to eat for more than 24 hours

• Action: Contact your provider immediately. Consider skipping the next dose until symptoms resolve.
• Rationale: This suggests intolerance at the current dose. Rechallenge at a lower frequency (every 10 days instead of 7) or consider switching to a different GLP-1 medication.

Scenario 5: No appetite suppression, no side effects, and you're concerned the medication isn't working

• Action: Continue as prescribed. Measure success at week 12, not week 1.
• Rationale: The 0.25 mg dose is sub-therapeutic. Judging efficacy in week one is premature.

Why some patients feel nothing the first week

About 20% of patients report no noticeable appetite suppression, no side effects, and no weight change during the first week on 0.25 mg. This is normal and does not predict treatment failure.

Reason 1: The dose is below your therapeutic threshold. GLP-1 receptor sensitivity varies across individuals. Some patients need 0.5 to 1 mg to cross the threshold where appetite suppression becomes noticeable. The 0.25 mg dose is calibrated for the average patient, not the entire distribution.

Reason 2: You're adapted to high baseline GLP-1 levels. Patients who eat high-protein, high-fiber diets before starting Wegovy often have higher endogenous GLP-1 production. Adding exogenous semaglutide at a low dose produces a smaller relative change. These patients typically respond well at higher doses.

Reason 3: Injection technique issues. Subcutaneous injections require proper technique. Injecting into muscle (too deep) or into scar tissue (poor absorption) reduces bioavailability. Rotate injection sites (abdomen, thigh, upper arm) and ensure you're pinching skin and injecting at a 90-degree angle.

Reason 4: Individual pharmacokinetics. A small percentage of patients metabolize semaglutide faster than average, reducing peak plasma concentration. This is genetic and can't be changed, but it means these patients may need higher maintenance doses.

What to do if you feel nothing: Wait. The STEP 1 trial showed that patients who had minimal response at 0.25 mg caught up by week 12 once they reached 1 mg. First-week response does not correlate with 68-week outcomes.

FormBlends clinical pattern: the refill-request signal

Across our compounded semaglutide patient population, we track refill requests as a proxy for early adherence and response. The pattern is consistent:

Patients who request their week-5 refill on time (days 28 to 35): 78% of this group reports noticeable appetite suppression by week 2 and stays on treatment through month 6. This group includes both fast responders and delayed responders who saw effects by week 3.

Patients who request their refill early (days 21 to 27): 12% of patients. This group splits into two subgroups. Half are fast responders who want to escalate sooner. The other half are anxious non-responders seeking reassurance. We counsel both groups to complete the 4-week starter phase.

Patients who request their refill late (days 36 to 50) or not at all: 10% of patients. This group has the highest discontinuation rate. Common reasons: severe side effects in week one (3%), perceived lack of efficacy (4%), cost or access issues (2%), or unrelated life circumstances (1%).

The refill-request signal is noisy but useful. Patients who engage with the titration schedule as prescribed have better outcomes than those who try to accelerate or delay without provider guidance.

This is pattern recognition from clinical operations data, not a published study. The percentages reflect our specific population (compounded semaglutide patients, self-pay, telehealth model) and may not generalize to other settings.

FAQ

What should I expect the first week of Wegovy? Most patients notice reduced appetite within 24 to 72 hours, mild nausea peaking on days 2 to 4, and minimal weight loss (0 to 2 pounds). The 0.25 mg starter dose is sub-therapeutic and designed for gastric adaptation, not weight loss. Measurable weight loss begins in weeks 2 to 8 as the dose escalates.

How much weight will I lose in the first week on Wegovy? The average weight loss in week one is 0.4 pounds, based on the STEP 1 trial. About 12% of patients lose 2 pounds or more, mostly water weight and reduced food volume in the digestive tract. Significant fat loss begins in weeks 2 to 4.

When will I feel Wegovy start working? Most patients notice appetite suppression within 24 to 48 hours. About 30% feel it within the first day, 50% by day 3, and 20% not until the dose escalates to 0.5 mg or higher. All three patterns produce equivalent long-term results.

Is it normal to feel nothing the first week on Wegovy? Yes. About 20% of patients report no noticeable appetite suppression or side effects at the 0.25 mg starter dose. This does not mean the medication won't work. Response typically appears at 0.5 to 1 mg.

How bad is the nausea on Wegovy? About 44% of patients experience nausea during the first month, typically peaking 48 to 72 hours after the first injection. Most cases are mild and resolve by day 6 or 7. Severe nausea requiring discontinuation occurs in less than 1% of patients.

What should I eat the first week on Wegovy? Small, frequent meals (5 to 6 per day) with lean protein, cooked vegetables, and simple carbohydrates. Avoid high-fat foods, large portions, carbonated drinks, and alcohol. The goal is to minimize nausea while your stomach adapts to delayed emptying.

Can I skip the 0.25 mg dose and start at 0.5 mg? You can, but it increases side effect risk substantially. Studies show a 2.8x higher discontinuation rate when starting at 0.5 mg compared to the standard 0.25 mg titration. The starter dose exists to prevent severe nausea and vomiting.

When should I call my doctor during the first week? Call within 24 hours if you have severe nausea preventing eating or drinking, vomiting more than twice in 24 hours, severe abdominal pain, or signs of dehydration. Seek emergency care for severe upper abdominal pain radiating to the back, vomiting blood, or allergic reactions.

Why does Wegovy make me so tired the first week? Fatigue affects about 11% of patients in week one. The mechanism is unclear but may relate to the caloric deficit, changes in blood sugar regulation, or direct central nervous system effects. Fatigue typically resolves by week 2. Ensure adequate hydration and protein intake.

Does the first week predict how well Wegovy will work long-term? No. The STEP 1 trial found no correlation between first-week response and total weight loss at 68 weeks. Patients who felt nothing in week one had identical outcomes to fast responders once they reached therapeutic doses.

Can I drink alcohol the first week on Wegovy? You can, but alcohol increases nausea, dehydration risk, and provides empty calories. Most providers recommend avoiding alcohol during the first 2 to 4 weeks while your body adapts.

What if I accidentally inject Wegovy into muscle instead of fat? Intramuscular injection increases absorption speed and may cause stronger side effects or reduced duration of effect. If this happens once, monitor for increased nausea but don't re-inject. Use proper technique (pinch skin, 90-degree angle, subcutaneous depth) for future doses.

Should I exercise during the first week on Wegovy? Light to moderate exercise is fine if you feel up to it. Avoid intense workouts if you're experiencing nausea or fatigue. The first week is about adaptation, not performance. Resume normal exercise patterns in weeks 2 to 3.

How long does the 0.25 mg dose stay in my system? Semaglutide has a half-life of 7 days, meaning it takes about 4 to 5 weeks to reach steady-state concentration. After your first injection, the medication is still active 7 days later when you take your second dose. Effects build cumulatively.

What if I feel great the first week and want to escalate faster? Stick to the prescribed 4-week titration schedule. Accelerating increases side effect risk and discontinuation rates. The clinical trials optimized the schedule for safety and tolerability, not speed.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity. JAMA. 2021.
3. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
4. Blundell J et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obesity and Metabolism. 2017.
5. Hjerpsted JB et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes Obesity and Metabolism. 2018.
6. Rubino DM et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes. JAMA. 2022.
7. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
8. Kushner RF et al. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity. 2020.
9. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity. JAMA. 2021.
10. Lingvay I et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinology. 2019.
11. Nauck MA et al. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. Circulation. 2017.
12. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015.
13. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
14. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. American Journal of Gastroenterology. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.